Skip to content
Screener

Intellia Therapeutics NTLA Total Liabilities & Equity

Total Liabilities & Equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.99B+0.3%
ALN
Alnylam PharmaceuticalsALNY
$5.56B+21.7%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$2.73B+25.8%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$1.48B+0.9%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$230.44M-3.0%
Prime Medicine logo
Prime MedicinePRME
$249.04M-10.7%

Other financials

Income statement

See full
Revenue$7.7M-46.2%
Operating income-$112.8M-2.5%
Net income-$106.6M-5.3%
EPS (diluted)-$0.80+18.4%

Balance sheet

See full
Cash & equivalents$106.1M-32.0%
Total debt$73.4M-28.4%
Total equity$727.7M+202%
Total assets$857.2M-4.6%

Cash flow

See full
Operating cash flow-$83.1M+16.6%
CapEx$1.8M+657%
Free cash flow-$84.9M+15.0%

Valuation

See full
Market cap$1.68B+45.7%
Enterprise value$1.65B+49.8%
P/S28.2×+6.4×

Profitability

See full
Operating margin-711.7%-149pp
Net margin-672.2%-139pp
FCF margin-586%-123pp

Returns & leverage

See full
Return on equity-56.3%-1.5pp
Debt / equity0.1×
Current ratio6.6×+1.5×

Where this comes from

Reported directly by Intellia Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Intellia Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337952
Line itemJune 30,2026December 31,2025
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, $0.0001 par value; 240,000,000 shares authorized at June 30, 2026 and December 31, 2025; 140,018,200 and 116,317,060 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1412
Additional paid-in capital3,521,6813,260,444
Accumulated other comprehensive (loss) income(1,030)1,032
Accumulated deficit(2,792,959)(2,590,094)
Total stockholders’ equity727,706671,394
Total liabilities and stockholders’ equity$857,164$842,127

Item 1. Financial Statements

FAQ

What is Intellia Therapeutics's total liabilities & equity?
Intellia Therapeutics (NTLA) reported total liabilities & equity of $857.16M in Q2 2026.
How has Intellia Therapeutics's total liabilities & equity changed year-over-year?
Intellia Therapeutics's total liabilities & equity decreased by 4.6% year-over-year, from $898.89M to $857.16M.
What is the long-term trend for Intellia Therapeutics's total liabilities & equity?
Over 5 years (2020 to 2025), Intellia Therapeutics's total liabilities & equity has grown at a 4.5% compound annual growth rate (CAGR), from $676.32M to $842.13M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Intellia Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude